Arbutus Biopharma Logo
Tekmira Announces Proposed Public Offering
08 juin 2011 16h02 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 8, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira's LNP Delivery Technology Enables Proof of RNAi in Man and Clinical Activity
06 juin 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 6, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided comments on...
Arbutus Biopharma Logo
Tekmira Files Amended Complaint in Alnylam Litigation
03 juin 2011 17h19 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, June 3, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Arbutus Biopharma Logo
Tekmira Expands Oncology Pipeline With RNAi Therapeutic Targeting Novel Cancer Genes WEE1 and CSN5
02 juin 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., June 2, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that it has...
Arbutus Biopharma Logo
Tekmira Presents LNP Technology Innovations at Scientific Symposium
26 mai 2011 16h47 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 26, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira to Present at the ThinkEquity 2nd Annual Healthcare Conference
19 mai 2011 16h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 19, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira and Bristol-Myers Squibb Expand Collaboration to Include Broader Applications of LNP Technology
17 mai 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 17, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Announces First Quarter 2011 Results
10 mai 2011 16h00 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., May 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced its financial and...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: First Quarter 2011 Operating Results and Corporate Update
04 mai 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Arbutus Biopharma Logo
Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
21 avr. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...